An Observational Pilot Study of Lumosity Computerized Cognitive Training

Status Completed

Clinical Trial Summary

In collaboration with the Mercy MS Achievement Center, Lumos Labs is proposing an open-label, 12-month pilot study of computerized cognitive training as part of the cognitive wellness program in order to evaluate (1) the user experience of Lumosity in individuals with MS, and (2) the efficacy of Lumosity for improving cognitive outcomes in individuals with MS.

Clinical Trial Description

Approximately 50 current members of the Mercy MS Achievement Center will be provided with 12-month premium access Lumosity accounts. Study participants must be ≥18 years of age, and currently members of the Achievement Center participating in the cognitive wellness program. Those who consent will be provided with an account activation code and instructed on how to sign up for Lumosity.

Upon creating an account, users would be asked to complete a short demographic survey (Information About You, which includes age, sex, race/ethnicity, education, occupation) and two additional short surveys: a Computer Experience Questionnaire and a Perceptions of Brain Training questionnaire. In addition, participants will be assessed with the Montreal Cognitive Assessment (MOCA), and be directed to take the Brain Performance Test (on a laptop or desktop computer) within the first 7 days of creating their account. If not conducted within the previous 3 months, participants would also be required to have the following assessments at baseline (i.e., within the first 7 days): Multiple Sclerosis Neuropsychological Questionnaire (MSNQ), Multiple Sclerosis Impact Scale-29 (MSIS-29), and Beck Depression Inventory (BDI). After one week of using Lumosity, and then every other month for 12 months, participants would be asked to complete a short questionnaire about their experience with Lumosity. Every 3 months, participants would repeat the BPT, MSNQ, and BDI; and every 6 months, they would repeat the MSIS. Finally, at the end of the study, the end of the study they would also repeat the MOCA. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02612935
Study type	Observational
Source	Lumos Labs, Inc.
Contact
Status	Completed
Phase	N/A
Start date	March 2015
Completion date	February 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05177523` - Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
Not yet recruiting	`NCT06053749` - An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
Not yet recruiting	`NCT06450600` - Enhancing Quality of Life in MS Patients Through Tailored Therapeutic Education	N/A
Recruiting	`NCT04926818` - Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis	Phase 3
Not yet recruiting	`NCT03624296` - Characterization of Cortical Injury in Early MS Patients: a 7T MRI Study	N/A
Terminated	`NCT04203498` - Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis	Phase 3
Active, not recruiting	`NCT04602390` - Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis	Phase 1
Completed	`NCT01804647` - Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease
Terminated	`NCT04907305` - Next-Gen MS: Feed-forward PRO Data for MS Research
Active, not recruiting	`NCT03456206` - Chronic Inflammatory Disease, Lifestyle and Risk of Disease
Completed	`NCT04705610` - Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography	N/A
Completed	`NCT01366027` - PRISM Registry: Pseudobulbar Affect Registry Series	N/A
Completed	`NCT03135249` - Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis	Phase 4
Recruiting	`NCT05633875` - Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis
Completed	`NCT02739542` - Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)	Phase 4
Completed	`NCT03177655` - Effect of Guided Imagery on Well-being in Patients With Multiple Sclerosis	N/A
Active, not recruiting	`NCT04777539` - Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis
Recruiting	`NCT02352194` - Physical Capacity and Rehabilitation of Patients With Multiple Sclerosis	N/A
Completed	`NCT02308579` - Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases	N/A
Completed	`NCT02019927` - Electric Stimulation of the Eye to Improve Vision After Trauma	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms